

Cell fate signaling: Research reveals an attractive target for cancer therapy

December 18 2019, by Leigh MacMillan



Cancer cell during cell division. Credit: National Institutes of Health

The protein kinase MELK is thought to affect cell cycle regulation, proliferation and mitosis. Overexpression of MELK impacts survival and proliferation of multiple cancer types, including glioblastomas and breast

cancer, but its molecular functions in cancer development are unclear.

Tina Iverson, Ph.D., and colleagues have identified a direct, high affinity interaction between MELK and the protein arrestin-3. Arrestins are best known for their regulation of G protein-coupled receptors; they also serve as scaffolds that facilitate cell signaling.

Using a combination of biophysical techniques and in-cell assays, the investigators demonstrated that the MELK/arrestin-3 interaction involves the kinase domain of MELK. They showed that the interaction reduces the numbers of [cells](#) in the S-phase of the cell cycle, during which DNA is replicated.

The role of MELK/arrestin-3 in cell fate signaling may make this interaction an attractive target for [cancer therapy](#), the authors reported in the November issue of *Cellular Signalling*.

More information: Nicole A. Perry et al. Arrestin-3 interaction with maternal embryonic leucine-zipper kinase, *Cellular Signalling* (2019). [DOI: 10.1016/j.cellsig.2019.109366](https://doi.org/10.1016/j.cellsig.2019.109366)

Provided by Vanderbilt University

Citation: Cell fate signaling: Research reveals an attractive target for cancer therapy (2019, December 18) retrieved 26 April 2024 from <https://medicalxpress.com/news/2019-12-cell-fate-reveals-cancer-therapy.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--